Malar J

Sequence variation does not confound the measurement of plasma PfHRP2 concentration in African children presenting with severe malaria.Ramutton T, Hendriksen IC, Mwanga-Amumpaire J, Mtove G, Olaosebikan R, Tshefu AK, Onyamboko MA, Karema C, Maitland K, Gomes E, Gesase S, Reyburn H, Silamut K, Chotivanich K, Promnares K, Fanello CI, von Seidlein L, Day NP, White NJ, Dondorp AM, Imwong M, Woodrow CJ
Malar J, (2012). 11:276

Human movement data for malaria control and elimination strategic planning.Pindolia DK, Garcia AJ, Wesolowski A, Smith DL, Buckee CO, Noor AM, Snow RW, Tatem AJ
Malar J, (2012). 11:205

Local perceptions of intermittent screening and treatment for malaria in school children on the south coast of Kenya.Okello G, Ndegwa SN, Halliday KE, Hanson K, Brooker SJ, Jones C
Malar J, (2012). 11:185

Inaugural meeting of the malaria policy advisory committee to the WHO: conclusions and recommendations.WHO Malaria Policy Advisory Committee Secretariat
Malar J, (2012). 11:137

The magnitude and trend of artemether-lumefantrine stock-outs at public health facilities in Kenya.Sudoi RK, Githinji S, Nyandigisi A, Muturi A, Snow RW, Zurovac D
Malar J, (2012). 11:37

Impact of insecticide-treated bed nets on malaria transmission indices on the south coast of Kenya.Mutuku FM, King CH, Mungai P, Mbogo C, Mwangangi J, Muchiri EM, Walker ED, Kitron U
Malar J, (2011). 10:356

Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries.Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, Solomon T, Munroe E, Chapman S, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Shewchuk T, Chavasse D, O'Connell KA
Malar J, (2011). 10:327

Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D
Malar J, (2011). 10:326

The ACTwatch project: methods to describe anti-malarial markets in seven countries.Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D
Malar J, (2011). 10:325

Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya.Lawford H, Zurovac D, O'Reilly L, Hoibak S, Cowley A, Munga S, Vulule J, Juma E, Snow RW, Allan R
Malar J, (2011). 10:281

Cost analysis of school-based intermittent screening and treatment of malaria in Kenya.Drake TL, Okello G, Njagi K, Halliday KE, Jukes MC, Mangham L, Brooker S
Malar J, (2011). 10:273

Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P, Greenwood B, Ofori-Anyinam O, Okech B, Villafana T, Carter T, Savarese B, Duse A, Reijman A, Ingram C, Frean J, Ogutu B
Malar J, (2011). 10:223

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.Vekemans J, Marsh K, Greenwood B, Leach A, Kabore W, Soulanoudjingar S, Asante KP, Ansong D, Evans J, Sacarlal J, Bejon P, Kamthunzi P, Salim N, Njuguna P, Hamel MJ, Otieno W, Gesase S, Schellenberg D
Malar J, (2011). 10:221

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.Lievens M, Aponte JJ, Williamson J, Mmbando B, Mohamed A, Bejon P, Leach A
Malar J, (2011). 10:222

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.Leach A, Vekemans J, Lievens M, Ofori-Anyinam O, Cahill C, Owusu-Agyei S, Abdulla S, Macete E, Njuguna P, Savarese B, Loucq C, Ballou WR
Malar J, (2011). 10:224

Global proteomic analysis of plasma from mice infected with Plasmodium berghei ANKA using two dimensional gel electrophoresis and matrix assisted laser desorption ionization-time of flight mass spectrometry.Gitau EN, Kokwaro GO, Newton CR, Ward SA
Malar J, (2011). 10:205

Treatment of African children with severe malaria - towards evidence-informed clinical practice using GRADE.Musila N, Opiyo N, English M
Malar J, (2011). 10:201

The clinical burden of malaria in Nairobi: a historical review and contemporary audit.Mudhune SA, Okiro EA, Noor AM, Zurovac D, Juma E, Ochola SA, Snow RW
Malar J, (2011). 10:138

Self-reported fever, treatment actions and malaria infection prevalence in the northern states of Sudan.Elmardi KA, Noor AM, Githinji S, Abdelgadir TM, Malik EM, Snow RW
Malar J, (2011). 10:128

A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers.Chilengi R, Juma R, Abdallah AM, Bashraheil M, Lodenyo H, Nyakundi P, Anabwani E, Salim A, Mwambingu G, Wenwa E, Jemutai J, Kipkeu C, Oyoo GO, Muchohi SN, Kokwaro G, Niehues T, Lang T, Nzila A
Malar J, (2011). 10:63